Skip to main content

Table 2 Patient and tumor information including: tumour-type: Merkel cell carcinoma (MCC), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) or normal skin (NS); sample date; disease stage; level of MCPyV large T-antigen mRNA expression: high (H), medium (M), low (L) or no expression (N); mean (SD) TrkA and TrkAIII percentage of total TrkA (TrkA + TrkAIII) RT-PCR levels; mean (SD) densitometric TrkA and TrkAIII ratios to 18S rRNA RT-PCR levels; anti-TrkA and Y490 phosphorylated TrkA (anti-pY490 TrkA) immunoreactivity in tissue samples: strong (S), medium (M), weak (W) or negative (N); patient therapy: surgery (S) and locoregional Melphalan chemotherapy (C)

From: A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target

Patient

Date of sample (m/y)

Stage

Large T-ag

%TrkA Mean (SD)

%TrkAIII Mean (SD)

Mean (SD) Ratio TrkA:18S rRNA

Mean (SD) Ratio TrkAIII:18S rRNA

IF anti-TrkA

IF anti-pY490 TrkA

Therapy

MCC

 1

06–2014 (i)

IV

H

1.88 (4.5)

98.12 (4.5)

0.016 (0.002)

0.834 (0.03)

S

S

S/C

09–2014 (ii)

IV

H

23.4 (8.4)

76.6 (8.4)

0.036 (0.007)

0.12 (0.01

M

M

S/C

12–2014 (iii)

IV

M/H

23.1 (6.5)

76.9 (6.5)

0.08 (0.001)

0.44 (0.02)

S

M

S/C

08–2015 (iv)

IV

H

8.6 (5.4)

91.4 (5.4)

0.034 (0.001)

0.4 (0.01)

M

M

S/C

 2

02–2008 (i)

IV

H

31.9 (4.5)

68.1 (4.5)

0.2 (0.01)

0.43 (0.02)

S

S

S/C

02–2008 (ii)

IV

H

1.3 (4.2)

98.7 (4.2

0.003 (0.0001)

0.26 (0.02)

S

S

S/C

02–2008 (iii)

IV

H

1.9 (6.1)

98.1 (6.1)

0.002 (0.0001)

0.2 (0.01)

M

S

S/C

 3

08–2011 (i)

IV

M

0.4 (4.2)

99.6 (4.2)

0.003 (0.0002)

0.68 (0.03)

S

S

S/C

08–2011 (ii)

IV

M/H

0.8 (8.4)

99.2 (8.4)

0.001 (0.0003)

0.09 (0.002)

M

W

S/C

 4

10–2012 (i)

I

M/H

6.2 (8.4)

93.8 (8.4)

0.02 (0.0013)

0.75 (0.02)

S

S

S

02–2013 (ii)

IV

M

12.4 (8.2)

87.6 (8.2)

0.002 (0.0001)

0.08 (0.002)

M

M

S

 5

02–2017

IIA

H

16.8 (7.9)

83.2 (7.9)

0.14 (0.005)

0.72 (0.002)

S

W

S

 6

09–2006

IIA

H

2.7 (8.4)

97.3 (8.4)

0.003 (0.0002)

0.09 (0.003)

L

N

S

 7

01–2010

IIA

L/M

28.5 (6.8)

71.5 (6.8)

0.08 (0.002)

0.19 (0.003)

L

M

S

 8

11–2007

IIB

M/H

58.5 (6.7)

41.5 (6.7)

0.2 (0.002)

0.18 (0.003)

S

M

S

 9

01–2013

IIA

H

47.4 (6.5)

52.6 (6.5)

0.19 (0.003)

0.22 (0.004)

S

S

S

 10

01–2006

IIIB

H

58.5 (6.7)

41.5 (6.7)

0.055 (0.001)

0.08 (0.003)

L

N

S

 11

01–2019

I

N

98.6 (0.2)

1.4 (0.2)

0.4 (0.002)

0.008 (0.001)

L

N

S

BCC

 12

01–2018

I

N

99.5 (0.04)

0.5 (0.04)

0.1 (0.02)

0.004 (0.0001)

N

N

S

 13

02–2018

I

N

99.8 (0.02)

0.2 (0.02)

0.04 (0.002)

0.08 (0.002)

W

N

S

 14

01–2019

I

L

99.9 (0.04)

0.1 (0.04)

0.213 (0.012)

0.02 (0.001)

N

N

S

SCC

15

02–2019

I

N

99.8 (0.02)

0.2 (0.02)

0.18 (0.002)

0.001 (0.0002)

N

N

S

16

01–2019

I

N

99.8 (0.05)

0.2 (0.05)

1.3 (0.03)

0.004 (0.0002)

S

N

S

17

03–2019

I

N

99.04 (0.05)

0.06 (0.05)

0.17 (0.02)

0.008 (0.0002)

W

N

S

Normal Skin

NS 1

  

N

99.6 (0.02)

0.4 (0.02)

0.45 (0.01)

0.0001 (0.00002)

S

N

S

NS 2

  

N

99.3 (0.01)

0.7 (0.01)

0.66 (0.023)

0.0001 (0.00002)

S

N

S